Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML

Acute myeloid leukemia (AML) is a common hematological malignancy. Intensive chemotherapy is the main treatment in fit patients. Retrospective studies have shown that Venetoclax is highly effective in elder AML patients with IDH2 and NPM1 mutations while in those with TP53 and FLT3 mutations, the combination of azacitidine with Venetoclax showed an increased remission rate without improved survival. Since AML is a highly heterogeneous disease, it is not clear which genetic type of adult AML patients would benefit from Venetoclax combined with intensive chemotherapy. Therefore, this study in

Trial Details

NCT ID
NCT06635681
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Daunorubicin
  • Cytarabine
  • Venetoclax
  • Azacitidine
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Patients who meet AML according to WHO (2022) or AML and MDS/AML defined by ICC standards.
  • Age ≥14 years old, ≤ 60 years old, male or female.
  • The physical status assessment (ECOG-PS) of the Eastern Oncology Collaboration group was 0-2 points.
  • Fulfill the requirements of the following laboratory tests (performed within 7 days prior to treatment) :

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →